A biotin‑streptavidin‑biotin bridge dramatically enhances cell fusion

Li,Jinhua; Yu,Xianzhong; Wagner,Thomas E.; Wei,Yanzhang

doi:10.3892/ol.2014.2067

A biotin‑streptavidin‑biotin bridge dramatically enhances cell fusion

Authors:
- Jinhua Li
- Xianzhong Yu
- Thomas E. Wagner
- Yanzhang Wei
View Affiliations

Affiliations: Department of Biotechnology, Greenville Technical College, Greenville, SC 29601, USA, Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA, Orbis Health Solutions, LLC., Greenville, SC 29601, USA
Published online on: April 15, 2014 https://doi.org/10.3892/ol.2014.2067
Pages: 198-202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the generation of hybrid cells by cell fusion plays a significant role in biotechnology and biomedicine, the low cell‑fusion rates and the limitation of large‑scale cell fusion for clinical applications of the two widely used approaches, polyethylene‑glycol (PEG)‑mediated cell fusion and electrofusion, hinder the application of this critical technology in certain key areas, including cancer immunotherapy. In the present study, a simple procedure that can not only significantly increase the heterologous cell fusion but is also capable of producing fused cells on a large scale is reported. A biotin‑streptavidin‑biotin (BSB) bridge was created by coating one to‑be‑fused cell with biotin and the other with biotin‑streptavidin. The BSB bridge enhances cell‑fusion rates induced with PEG fusion or electrofusion by 10‑30% depending on the cell types when compared with cell fusions without the bridge. The procedure described increases heterologous cell pairing and eliminates the alignment step required for the majority of electrofusions. Notably, it can be used to make large‑scale cell fusions for clinical applications.

View Figures

View References

1	Okada Y and Tadokoro J: The distribution of cell fusion capacity among several cell strains or cells caused by HVJ. Exp Cell Res. 32:417–430. 1963.
2	Okada Y, Yamada K and Tadokoro J: Effect of antiserum on the cell fusion reaction caused by HVJ. Virology. 22:397–409. 1964.
3	Okada Y, Kim J, Maeda Y and Koseki I: Specific movement of cell membranes fused with HVJ (Sendai virus). Proc Natl Acad Sci. 71:2043–2047. 1974.
4	Furusawa M, Nishimura T, Yamaizumi M and Okada Y: Injection of foreign substances into single cells by cell fusion. Nature. 249:449–450. 1974.
5	Frye LD and Edidin M: The rapid intermixing of cell surface antigens after formation of mouse-human heterokaryons. J Cell Sci. 7:319–335. 1970.
6	Singer SJ and Nicolson GL: The fluid mosaic model of the structure of cell membranes. Science. 175:720–731. 1972.
7	Rodriguez-Tomé P and Lijnzaad P: The radiation hybrid database. Nucleic Acids Res. 27:115–118. 1999.
8	Islam MQ, da Meirelles LS, Nardi NB, Magnusson P and Islam K: Polyethylene glycol-mediated fusion between primary mouse mesenchymal stem cells and mouse fibroblasts generates hybrid cells with increased proliferation and altered differentiation. Stem Cells Dev. 15:905–919. 2006.
9	Galfre G, Howe SC, Milstein C, Butcher GW and Howard JC: Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 266:550–552. 1977.
10	Margulies DH: Monoclonal antibodies: producing magic bullets by somatic cell hybridization. J Immunol. 174:2451–2452. 2005.
11	Wei Y, Li J and Wagner TE: Dendritoma vaccine for cancer. Curr Can Ther Rev. 5:134–141. 2009.
12	Avigan D, Rosenblatt J and Kufe D: Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol. 39:287–295. 2012.
13	Browning MJ: Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy. Hum Vaccin Immunother. 9:1545–1548. 2013.
14	Köhler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495–497. 1975.
15	Anné J and Peberdy JF: Conditions for induced fusion of fungal protoplasts in polyethylene glycol solutions. Arch Microbiol. 105:201–205. 1975.
16	Pontecorvo G: Production of mammalian somatic cell hybrids by means of polyethylene glycol treatment. Somatic Cell Genet. 1:397–400. 1975.
17	Zimmermann U, Vienken J, Halfmann J and Emeis CC: Electrofusion: a novel hybridization technique. Adv Biotechnol Processes. 4:79–150. 1985.
18	Hiraoka K, Yamamota S, Otsuru S, Nakai S, Tamai K, Morishita R, Ogihara T and Kaneda Y: Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol. 173:4297–4307. 2004.
19	Uekawa N, Nishioka T, Terauchi K, Ohta S, Sugimoto M, Shimada J and Maruyama M: Generation and characterization of novel monoclonal antibodies against murine and human TARSH proteins. Hybridoma (Larchmt). 26:381–385. 2007.
20	Bakker Schut TC, Kraan YM, Barlag W, de Leij L, de Grooth BG and Greve J: Selective electrofusion of conjugated cells in flow. Biophys J. 65:568–572. 1993.
21	Tomita M and Tsong TY: Selective production of hybridoma cells: antigenic-based pre-selection of B lymphocytes for electrofusion with myeloma cells. Biochim Biophys Acta. 1055:199–206. 1990.
22	Kimura Y, Gel M, Techaumnat B, Oana H, Kotera H and Washizu M: Dielectrophoresis-assisted massively parallel cell pairing and fusion based on field constriction created by a micro-orifice array sheet. Electrophoresis. 32:2496–2501. 2011.
23	Skelley AM, Kirak O, Suh H, Jaenisch R and Voldman J: Microfluidic control of cell pairing and fusion. Nat Methods. 6:147–152. 2009.
24	Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N and Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 223:77–92. 1999.